High-stability long-acting GLP-1 RAs derivative
Through liquid-liquid phase separation, GLP-1RAs derivatives designed, combined with E. coli expression vector, solve the problems of short half-life of existing GLP-1RAs drugs and complex biological expression processes, achieve high stability and long-term effectiveness, and simplify the process And meets green chemistry requirements.
Patent Information
- Application Number
- CN202310548328.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
The existing GLP-1RAs drugs have short half-life, resulting in unstable therapeutic effects. The biological expression process has many processes, large consumption of organic solvents and immunogenicity, making it difficult to meet the needs of high expression, simple process and environmentally friendly.
Using GLP-1RAs derivatives designed based on liquid-liquid phase separation, the GLP-1RAs amino acid sequence, ligation arm sequence and phase separation sequence are fused, and E. coli expression vector is used to achieve efficient expression, simplify the preparation process, extend the half-life of the drug and improve stability. .
It achieves high stability and long-term efficacy of GLP-1RAs drugs, simplifies the preparation process, avoids the use of a large number of organic reagents in the synthesis of peptides, meets green chemistry requirements, extends the half-life of the drug and improves stability.
Smart Images

Figure CN118994411A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of therapeutic peptides, and in particular to a novel high-stability long-acting GLP-1 RAs derivative, and a preparation method and application thereof. Background Art
[0002] Globally, with economic development and the gradual advancement of urbanization, unhealthy eating habits and sedentary lifestyles have become increasingly prevalent. Coupled with the aging of the population, the prevalence of type 2 diabetes (T2DM) has increased year by year. According to data provided by the International Diabetes Federation (IDF), approximately 573 million adults (aged 20-79) have diabetes, and this number is expected to increase to 643 million by 2030 and to 783 million by 2045 [1].
[0003] In recent years, the diabetes drug market has continued to expand. In addition to the first-line drug metformin[2], glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a dazzling class of diabetes treatment drugs. For a long time, the market for this type of diabetes drug has been almost monopolized by Eli Lilly and Novo Nordisk. Therefore, the development of new GLP-1RAs drugs is of great significance for improving the treatment effect of diabetes and expanding the market share of Chinese pharmaceutical manufacturers in the domestic market.
[0004] GLP-1 is a GLP-1RA that exhibits gluconic acid inhibition and glucose-dependent insulinotropic effects [3]. When glucose levels in the body rise, GLP-1 promotes insulin secretion, but has almost no such effect at normal glucose levels [4]. In addition, GLP-1 can inhibit the secretion of glucagon [5]. Therefore, GLP-1 has become an important research basis for the development of T2DM therapeutic drugs. The active fragments of GLP-1 are GLP-1 (7-36) and GLP-1 (7-37). However, the main pharmacological problem of natural GLP-1 is its short half-life. In humans and rats, GLP-1 is rapidly degraded to GLP-1 (9-36) amide by dipeptidyl peptidase-IV (DPP-IV), which acts as an endogenous GLP-1 receptor antagonist.
[0005] Currently, the industry has applied a variety of strategies such as amino acid modification, fatty acid derivatization, co-fusion of stable proteins and pegylation to modify the structure of GLP-1 in order to obtain a more stable polypeptide structure and a longer duration of action.
[0006] Exendin-4 has 53% homology with endogenous GLP-1 and is also a strong GLP-1 receptor agonist. US5424286A discloses a pharmaceutical composition containing exendin-4 and a method for treating diabetes and preventing hyperglycemia. US2008 / 0200390A1 discloses an exendin agonist with a polyamino acid modified at the C-terminus of exendin-4. WO2006 / 074600A1 discloses PEGylated exendin derivatives.
[0007] WO98 / 08871A and WO2006 / 097537A disclose GLP-1 derivatives with lipophilic substituents. US7141547B2 and US7452966B2 disclose GLP-1 fusion proteins containing albumin, which covalently fuse the GLP-1 active backbone to a large and stable carrier protein to extend the duration of action. WO 2004 / 093823A discloses PEGylated GLP-1 derivatives.
[0008] The main dosing methods of GLP-1RAs currently available in the international market include every two days, every three days or once a week, but there is still a need for the development of innovative long-acting GLP-1RA drugs in China.
[0009] The existing technology mainly synthesizes polypeptides by chemical synthesis, but the chemical method has the disadvantages of complicated processes and large consumption of organic solvents, which does not conform to the concept of green biomanufacturing. Therefore, the industry is seeking biological expression. US 2008 / 0032671A discloses a method for expressing acylated polypeptides in yeast, but it has the disadvantages of long expression cycle and easy to cause immunogenicity. Therefore, it is urgent to find a new polypeptide biological expression process to meet the requirements of high expression amount, simple process and environmental friendliness.
[0010] Liquid-Liquid Phase Separation (LLPS) of proteins describes the spontaneous separation of a high-concentration solution into two phases of high and low concentrations that coexist stably, manifested as droplets precipitating from a gel solution. Phase separation leads to a significant increase in local protein concentration, while forming an independent internal environment separated from the external environment. The internal environment also undergoes a certain degree of material exchange with the external environment, and the enrichment of materials strengthens the interaction between phase-separated molecules [6]. Under physiological conditions, intrinsically disordered regions (IDRs) can increase the likelihood of LLPS occurring in proteins containing this structure. The N-terminus of the eukaryotic initiation factor 4F subunit (eIF4G) has an IDR and is capable of LLPS.
[0011] References
[0012] [1]International Diabetes Federation.IDF Diabetes Atlas,10thedn.Brussels,Belgium:International Diabetes Federation,2021.
[0013] [2]HoJin Shin,Sebastian Schneeweiss,Robert J.Glynn,etal.Cardiovascular Outcomes in Patients Initiating First-Line Treatment ofType 2Diabetes With Sodium–Glucose Cotransporter-2Inhibitors VersusMetformin:A Cohort Study[J].Ann Intern Med.2022;175:927-937.
[0014] [3]Das,A.,Geetha,K.M.&Hazarika,I.Contemporary Updates on thePhysiology of Glucagon like Peptide-1and Its Agonist to Treat Type 2DiabetesMellitus[J].Int J Pept Res Ther 26,1211–1221(2020).
[0015] [4]A.R.Meloni,M.B.Deyoung,C.Lowe,D.G.Parkes GLP-1receptor activatedinsulin secretion from pancreatic beta-cells:mechanism and glucose dependenceDiabetes Obes[J].Metab.,15(2013),pp.15-27.
[0016] [5]Trujillo JM, Nuffer W, Smith BA. GLP-1receptor agonists: an updated review of head-to-head clinical studies[J]. Therapeutic Advances in Endocrinology and Metabolism. 2021; 12.
[0017] [6]SABARI BR,DALL'AGNESE A,YOUNG R A.Biomolecular Condensates in theNucleus[J].Trends Biochem Sci, 2020,45(11):961-977. Summary of the invention
[0018] In order to solve the problem of short half-life of GLP-1RAs, the present invention studies and develops a GLP-1RAs derivative based on liquid-liquid phase separation design, and a method for efficiently expressing the GLP-1RAs derivative.
[0019] For ease of description, herein, "polypeptide" and "peptide" refer to a compound composed of at least 5 constituent amino acids connected by peptide bonds. The constituent amino acids can be natural amino acids as well as synthetic amino acids. An "analog" of a polypeptide refers to a modified peptide, wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues, and / or wherein one or more amino acid residues have been deleted from the peptide, and / or wherein one or more amino acid residues have been added to the peptide. A "derivative" of a polypeptide refers to a chemically modified peptide or an analog thereof, wherein at least one substituent is not present in the unmodified peptide or its analog, i.e., a peptide that has been covalently modified. Typical modifications are amides, sugars, alkyls, acyl groups, esters, and the like. A simple system is commonly used in the art to describe fragments and analogs of GLP-1RAs, for example, GLP-1 (1-37) refers to a GLP-1 polypeptide having all amino acids from the 1st (N-terminus) to the 37th (C-terminus); GLP-1 (7-37) refers to a GLP-1 polypeptide having all amino acids from the 7th (N-terminus) to the 37th (C-terminus), and its amino acid sequence is shown as SEQ ID No. 1 herein; Gly 8 -GLP-1(7-37) refers to a GLP-1 fragment formed by deleting amino acid residues 1 to 6 from GLP-1 and replacing the naturally occurring amino acid residue at position 8 (Ala) with Gly. 34(Nε-tetradecanoyl)-GLP-1(7-37) represents GLP-1(7-37) in which the ε-amino group of the Lys residue at position 34 has been tetradecanoylated. 35 Exendin-4(1-39) represents exendin-4(1-39) lacking the Ala residue at position 35.
[0020] The first aspect of the present invention is to provide a GLP-1RAs derivative, which is a fusion protein with high stability and long-term effect, which can stimulate GLP-1R, promote insulin secretion and lower blood sugar.
[0021] According to the present invention, the GLP-1RAs derivative comprises the amino acid sequence of GLP-1RAs, a linker sequence and a phase separation sequence. In one embodiment of the present invention, the GLP-1RAs derivative is composed of the amino acid sequence of GLP-1RAs-linker sequence-phase separation sequence from the N-terminus to the C-terminus. In another embodiment of the present invention, the GLP-1RAs derivative is composed of the phase separation sequence-linker sequence-GLP-1RAs amino acid sequence from the N-terminus to the C-terminus.
[0022] The GLP-1RAs are GLP-1 (7-37) or its analogs, or derivatives of GLP-1 (7-37), or derivatives of GLP-1 (7-37) analogs, or exendin-4 (1-39) or its analogs, or derivatives of exendin-4 (1-39), or derivatives of exendin-4 (1-39) analogs. The analogs and derivatives can be described in patents such as CN1232470A, US5424286A, US2008 / 0200390A1, WO2006 / 097537A, US7141547B2, and US7452966B2.
[0023] In some embodiments of the present invention, the analog of GLP-1 (7-37) is GLP-1 (7-36), wherein the amino acid at position 8 of GLP-1 (7-37) is Ala, Gly, Val, Leu, Ile, Lys, Aib (α-aminoisobutyric acid), (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid or (1-aminocyclooctyl) carboxylic acid; the amino acid at position 22 is Gly, Glu or Aib; the amino acid at position 26 is Lys or Arg; the amino acid at position 34 is Lys, Glu, Asn or Arg; and the amino acid at position 36 is Arg, Gly or Lys. In one embodiment of the present invention, the analog of GLP-1 (7-37) is Gly8 ,Glu 22 ,Gly 36 GLP-1(7-37), the amino acid sequence is shown in SEQ ID No.2.
[0024] An example of a derivative of GLP-1(7-37) is Lys 34 (Nε-tetradecanoyl)-GLP-1(7-37) and the like. An example of a derivative of a GLP-1(7-37) analog is Nε26-((4S)-4-(hexadecanoylamino)-carboxy-butyryl)[Arg 34 , Lys 26 ]GLP-1-(7-37), etc.
[0025] The amino acid sequence of exendin-4(1-39) is shown in SEQ ID NO: 7. Exendin-4(1-39) analogs such as exendin-4(1-31), Y 31 Exendin-4(1-31), desAla 35 exendin-4(1-39), des-Pro 36 exendin-4(1-39), des-Pro 36 ,Pro 37 exendin-4(1-39), des-Pro 36 ,Pro 37 ,Pro 38 exendin-4(1-39), etc.
[0026] The amino acid sequences of exemplary GLP-1RAs in the present invention are as follows:
[0027] Sequence number Amino acid sequence SEQ ID No. 1, GLP-1 (7-37) HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG <![CDATA[SEQ ID No.2,Gly 8 ,Glu 22 ,Gly 36 GLP-1(7-37)]]> HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG SEQ ID No.7, exendin-4 (1-39) HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
[0028] The tether sequence can use a commonly used flexible tether sequence in the art, including but not limited to a GS tether sequence, a DDK tether sequence, or a combination of these tether sequences. In one embodiment of the present invention, the tether sequence is GGGGSGGGGSGGGGS (SEQ ID No. 3).
[0029] The phase separation sequence is the amino acid sequence of eIF4G (13-97) as shown in SEQ ID No. 4 or an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or about 100% homology to the sequence. SEQ ID No. 4: QQANGYKKFPPHDNQYSGAQQSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRNNSQGNAQYYNNRFNNGYRLNNNDYN.
[0030] In one embodiment of the present invention, the amino acid sequence of the GLP-1RAs derivative is shown in SEQ ID No. 5. SEQ ID No. 5: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSQQANGYKKFPPHDNQYSGAQQSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRNNSQGNAQYYNNRFNNGYRLNNNDYN.
[0031] The present invention also provides a nucleic acid encoding the GLP-1RAs derivative described in the first aspect of the present invention.
[0032] The present invention also provides an expression vector comprising the nucleic acid described above. In some embodiments, the expression vector is a plasmid vector. In some embodiments, the plasmid vector includes but is not limited to pET-22a(+), pET-28a(+), pET-30a(+), pET-33b(+), etc.
[0033] The present invention also provides a host cell, the host cell comprising the expression vector described above. In some embodiments, the host cell is Escherichia coli, such as Escherichia coli BL21 (DE3), Escherichia coli Rosetta (DE3), Escherichia coli Mach1-T1 and / or Escherichia coli DH5α.
[0034] The present invention also provides a pharmaceutical composition comprising the GLP-1RAs derivative according to the first aspect of the present invention and a pharmaceutically acceptable carrier.
[0035] The pharmaceutical composition is in a form suitable for oral, parenteral (including subcutaneous (sc), intravenous (iv), intramuscular (im), epidural, direct intracerebral and intraperitoneal (ip)), rectal, intratracheal, intranasal, dermal, intravaginal, buccal, ocular or pulmonary administration, preferably in a form suitable for subcutaneous or oral administration. The pharmaceutical composition can be in conventional forms, such as capsules, tablets, sprays, topical forms, liquid or semi-liquid forms such as solutions, suspensions, dispersions, emulsions, micelles or liposomes. Liquid compositions are preferably suitable for subcutaneous administration. These pharmaceutical compositions can be prepared by methods well known to those skilled in the art.
[0036] In one embodiment of the present invention, the pharmaceutical composition of the present invention is administered subcutaneously. In another embodiment of the present invention, the pharmaceutical composition of the present invention is administered orally, in which case, the preferred administration form is a tablet or capsule.
[0037] The pharmaceutically acceptable carrier can be a conventional solid or liquid carrier. Examples of solid carriers include but are not limited to lactose, sucrose, cyclodextrin, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid or cellulose lower alkyl ethers, etc. Examples of liquid carriers include but are not limited to syrup, peanut oil, olive oil, phospholipids, sterols, fatty acids, fatty acid amines, polyoxyethylene, isotonic buffer and water, etc.
[0038] The present invention also provides the use of the GLP-1RAs derivatives described in the first aspect of the present invention or the pharmaceutical composition containing the GLP-1RAs derivatives in the preparation of drugs for preventing or treating or delaying the progression or onset of the following diseases: type I and type II diabetes, impaired glucose tolerance, insulin resistance, diabetic complications (nephropathy, retinopathy, neuropathy, cataracts), hyperglycemia, hypercholesterolemia, dyslipidemia, hyperlipidemia, obesity, hypertension, syndrome X, atherosclerosis, etc.
[0039] In one embodiment of the invention, the medicament is for use in delaying or preventing the development of type II diabetes.
[0040] In one embodiment of the invention, the medicament is for reducing food intake, reducing β-cell apoptosis, increasing β-cell function and β-cell mass and / or restoring glucose sensitivity of β-cells.
[0041] The treatment using the GLP-1RAs derivatives or their pharmaceutical compositions according to the present invention can also be combined with one or more other pharmacologically active substances, such as those selected from antidiabetic drugs, anti-obesity drugs, appetite regulators, antihypertensive drugs, preparations for treating and / or preventing complications caused by or associated with diabetes, and preparations for treating and / or preventing complications and disorders caused by or associated with obesity.Examples of such pharmacologically active substances are: insulin, sulfonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and / or glycogenolysis, glucose uptake regulators, compounds regulating lipid metabolism such as antihyperlipidemic agents such as HMG CoA inhibitors (statins), gastric inhibitory polypeptide (GIP analogs), compounds that reduce food intake, RXR agonists, and agents that act on ATP-dependent potassium channels of beta cells; cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide; beta blockers such as allelol, atenolol, timolol, indolol, naproxenol, and metoprolol; ACE (angiotensin-converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosenopril, lisinopril, alatriopril il, quinapril and ramipril, calcium channel blockers such as nifedipine, diclofenac, nifedipine, isradipine, nimodipine, diltiazem and verapamil, and alpha blockers such as doxazosin, mefenamic acid, prazosin and terazosin; CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, PYY agonists, PYY2 agonists, PYY4 agonists, mixed PPY2 / PYY4 agonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte contracting hormone) antagonists, CCK (cholecystokinin) agonists, serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, mixed serotonin and norepinephrine compounds, 5HT (serotonin) agonists, bombesin agonists, ganglioside peptide antagonists, growth hormone, growth hormone releasing compounds, TRH (thyrotropin-releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptine, doprexin), lipase / amylase inhibitors, RXR (retinoid X receptor) modulators, TRβ agonists; histamine H3 antagonists, gastric inhibitory polypeptide agonists or antagonists (GIP analogs), gastrin and gastrin analogs.
[0042] The present invention also relates to a method for preparing the GLP-1RAs derivatives using recombinant DNA technology, which comprises the following steps: (a) introducing a nucleic acid sequence encoding the GLP-1RAs derivatives into a host cell, (b) cultivating the host cell, and (c) isolating the GLP-1RAs derivatives from the culture.
[0043] In the present invention, in order to improve the expression and purification efficiency of the GLP-1RAs derivative, a fusion protein containing the GLP-1RAs derivative sequence is expressed by using an appropriate expression vector, and its amino acid sequence is shown in SEQ ID No. 6. The fusion protein is a polypeptide MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSDDDDK fused to the N-terminus of the GLP-1RAs derivative sequence, which contains a tag and an enterokinase cleavage site DDDDK.
[0044] The nucleic acid sequence encoding the GLP-1RAs derivative shown in SEQ ID No.5 is introduced into a host cell, the host cell is cultured, the fusion protein shown in SEQ ID No.6 is isolated from the culture, the fusion protein is purified by HPLC, the fusion protein is cleaved with enterokinase, and then purified again by HPLC to obtain the GLP-1RAs derivative shown in SEQ ID No.5.
[0045] In one embodiment, the expression vector is pET-28a(+).
[0046] In some embodiments of the present invention, the host cell is Escherichia coli, such as Escherichia coli BL21 (DE3), Escherichia coli Rosetta (DE3), Escherichia coli Mach1-T1 and / or Escherichia coli DH5α.
[0047] In one embodiment, the recombinant Escherichia coli is cultured at 35-40°C for 10-12 hours to obtain a seed solution, which is then inoculated into a culture medium at an inoculum size of 0.1%-2% (v / v) and cultured until the OD600 value of the fermentation solution reaches 0.6-0.8, and IPTG is added at a final concentration of 0.05-1 mM for induction. The fermentation is terminated after induction at 25-40°C for 6-12 hours, and the fermented bacteria are crushed and extracted, preliminarily purified by HPLC, and then digested with enterokinase at 4-37°C for 8-72 hours and purified again by HPLC to obtain the GLP-1RAs derivatives of the present invention.
[0048] In one embodiment, the bacterial cells are suspended in a disruption buffer, the bacterial cells are disrupted and then centrifuged to collect the obtained inclusion body precipitate, the inclusion body precipitate is washed with a washing buffer, the washed inclusion bodies are dissolved by adding an inclusion body dissolution buffer at a protein concentration of 5 to 55 g / L at a pH of 12-13, more preferably by adding an inclusion body dissolution buffer at a protein concentration of 20 to 30 g / L, and the dissolved fusion protein is centrifuged, preferably at 4°C, to remove insoluble impurities.
[0049] The components of the fragmentation buffer are 24-26 mM Tris-HCl, 9-11 mM imidazole, 170-190 mM NaCl, pH 7.9-8.1.
[0050] The washing buffer comprises 24-26 mM Tris-HCl, 9-11 mM imidazole, 170-190 mM NaCl, 9-11 mM EDTA, 1.5-2.5% Tween 20, pH 7.9-8.1.
[0051] The inclusion body dissolution buffer comprises 24-26 mM Tris-HCl, 1.5-2.5% Tween 20, and pH 12.9-13.1.
[0052] In one embodiment, the pH of the fusion protein supernatant solution after centrifugation is adjusted to 8-9, preferably pH 9, and the solution becomes slightly turbid. An anionic surfactant, preferably 0.2-0.4% sodium lauryl sarcosine (SLS), is added to clarify the solution.
[0053] In one embodiment, the clear solution containing SLS is passed through a membrane for HPLC purification.
[0054] HPLC conditions: Using C18 reverse phase column:
[0055] Phase A: Ultrapure water containing 0.05% (v / v) TFA
[0056] Phase B: 80% (v / v) acetonitrile-water solution containing 0.05% (v / v) TFA
[0057] Flow rate: 1~6mL / min
[0058] Detection wavelengths: 215nm and 254nm.
[0059] The enzyme digestion buffer comprises 24-26 mM Tris-HCl, pH 7.9-8.1.
[0060] The present invention has the following advantages over the prior art:
[0061] Using genetic engineering technology, inclusion bodies are obtained through Escherichia coli fermentation, which simplifies the preparation process steps and avoids the use of large amounts of organic reagents in peptide synthesis, meeting the requirements of green chemistry; by integrating phase separation sequences, the half-life of the drug relative to natural GLP-1 is extended, thereby achieving better drug stability.
[0062] definition:
[0063] “And / or” will be considered as a specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” used in phrases such as “A and / or B” is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Similarly, the term “and / or” used in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0064] "Including" and "comprising" have the same meaning, are intended to be open ended and allow but not require the inclusion of additional elements or steps. When the terms "including" or "comprising" are used herein, the terms "consisting of" and / or "consisting essentially of" are also included and disclosed.
[0065] Homology: As used herein, the term "homology" refers to the overall relatedness between polymer molecules, for example, between nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Typically, the term "homology" means the evolutionary relationship between two molecules. Thus, two homologous molecules will have a common evolutionary ancestor. In the context of the present disclosure, the term homology includes identity and similarity.
[0066] In some embodiments, polymer molecules are considered to be "homologous" to each other if at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of the monomers in the molecule are identical (identical monomers) or similar (conservative substitutions). The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences).
[0067] Identity: As used herein, the term "identity" refers to the overall monomer conservation between polymer molecules, such as between polynucleotide molecules (eg, DNA molecules and / or RNA molecules) and / or between polypeptide molecules.
[0068] Suitable software programs are available for the alignment of both protein and nucleotide sequences, for example, Bl2seq, Needle, Stretcher, Water or Matcher and the like. BRIEF DESCRIPTION OF THE DRAWINGS
[0069] Figure 1 This is the process route for fermentation expression in this application
[0070] Figure 2 This is the construction diagram of the recombinant plasmid
[0071] Figure 3 is the HPLC spectrum of the fusion protein shown in SEQ ID No.6
[0072] Figure 4 The HPLC spectrum and mass spectrum of the target protein shown in SEQ ID No.5 after enzyme digestion
[0073] Figure 5 is the serum stability of the tested sample
[0074] Figure 6 is the concentration response curve of the test sample
[0075] Figure 7 The confocal observation results of phase separation of the protein shown in SEQ ID No.5 at different PEG concentrations
[0076] Figure 8 The effect of HSA on the phase separation of the protein shown in SEQ ID No.5
[0077] Fig. 9 The effect of temperature on the phase separation of the protein shown in SEQ ID No.5
[0078] Fig.10 This is the result of glucose tolerance test after oral administration of the protein shown in SEQ ID No.5. DETAILED DESCRIPTION
[0079] The present invention is further described below in conjunction with the examples. It should be noted that the examples cannot be used as a limitation on the protection scope of the present invention, and those skilled in the art understand that any improvements and changes made on the basis of the present invention are within the protection scope of the present invention.
[0080] The conventional reagents used in the following examples are all commercially available, and the biological experiments performed are all conventional biological experiments in the art and can be performed according to the instructions in the corresponding experimental manual or kit instructions.
[0081] Example 1: Construction of recombinant engineering bacteria
[0082] A recombinant engineered bacterium expressing the amino acid sequence shown in SEQ ID No. 5 was constructed. Considering that the pET-28a(+) vector carries an N-terminal His / Thrombin / T7 protein tag and a selectable C-terminal His tag, and the N-terminus of the target protein shown in SEQ ID No. 5 is its main functional region, in order not to change the functional activity of the N-terminus of the target protein, an enterokinase cleavage site (DDDDK) was introduced at its N-terminus, so that the protein can be cleaved after protein expression and purification, thereby obtaining the target protein shown in SEQ ID No. 5 with complete activity. The amino acid sequence of the complete fusion protein with enterokinase cleavage site and target protein expressed by pET-28a(+) vector is SEQ ID No.6: MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSDDDDKHGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSQQANGYKKFPPHDNQYSGAQQSQPNNHYNENLYSAREPHNNKQYQSKNGKYGTNKYNNRNNSQGNAQYYNNRFNNGYRLNNNDYN. The construction diagram of the recombinant plasmid is shown in the figure below: Figure 2 shown.
[0083] The recombinant plasmid was commissioned to be synthesized by a biotechnology company, and an appropriate amount of the plasmid was taken for heat shock transformation, and the recombinant plasmid was transformed into competent cells Escherichia coli Rosetta (DE3) to construct a recombinant engineered bacterium.
[0084] Example 2: Expression and purification of polypeptide fusion protein
[0085] The recombinant Escherichia coli was inoculated in TB medium and cultured at 37°C for 12 hours to obtain a seed solution, which was then inoculated into TB medium at a 2% (v / v) inoculation amount and cultured until the OD600 value of the fermentation liquid reached 0.6-0.8, and IPTG with a final concentration of 0.5 mM was added for induction. The fermentation was terminated after induction at 25°C for 12 hours. The bacterial cells were collected, suspended in a crushing buffer, crushed by a high-pressure homogenizer, and then centrifuged to collect the resulting inclusion body precipitate. The crushing buffer contained 25 mM Tris-HCl, 10 mM imidazole, 180 mM NaCl, and pH 8.0.
[0086] The inclusion body precipitate was washed with a washing buffer, wherein the washing buffer contained 25 mM Tris-HCl, 10 mM imidazole, 180 mM NaCl, 10 mM EDTA, 2% Tween 20, pH 8.0.
[0087] The washed inclusion bodies were dissolved in inclusion body dissolution buffer at a pH of 13 according to a protein concentration of 20-30 g / L. The inclusion body dissolution buffer contained 25 mM Tris-HCl, 2% Tween 20, and pH 13.
[0088] The dissolved fusion protein was centrifuged at 4°C to remove insoluble impurities. The pH of the supernatant after centrifugation was adjusted to 9. The solution was slightly turbid. 0.3% SLS was added to clarify the solution and then filtered through a membrane. The fusion protein was purified by HPLC using a C18 preparative column (YMC-PackODS-A) and lyophilized to obtain a pure fusion protein. The HPLC conditions were as follows:
[0089] Phase A: Ultrapure water containing 0.05% (v / v) TFA
[0090] Phase B: 80% (v / v) acetonitrile-water solution containing 0.05% (v / v) TFA
[0091] Ultrasonic degassing after 0.22μm filter membrane filtration
[0092] Flow rate: 6mL / min
[0093] Initial B phase ratio: 10%
[0094] Detection wavelengths: 215nm and 254nm.
[0095] The HPLC results of the fusion protein are as follows Figure 3 The component with a retention time of 42.83 min is the expressed fusion protein shown in SEQ ID No.6.
[0096] The lyophilized fusion protein was dissolved in a digestion buffer containing 25 mM Tris-HCl, pH 8.0, and digested with enterokinase at 25°C for 16 h. The digested solution was passed through a membrane and separated by HPLC using a C18 analytical column (ZORBAX 300SB-C18) and identified by mass spectrometry.
[0097] The HPLC conditions are as follows:
[0098] Phase A: Ultrapure water containing 0.05% (v / v) TFA
[0099] Phase B: 80% (v / v) acetonitrile-water solution containing 0.05% (v / v) TFA
[0100] Ultrasonic degassing after 0.22μm filter membrane filtration
[0101] Flow rate: 1mL / min
[0102] Initial B phase ratio: 10%
[0103] Detection wavelengths: 215nm and 254nm.
[0104] The conditions for mass spectrometry identification are as follows:
[0105] The molecular weight of the peptide was identified using a high performance liquid chromatography-quadrupole electrostatic field orbital trap high-resolution mass spectrometer, the positive ion mode was set, the ion source was HESI, and the scan was performed at 500-1200 m / z.
[0106] The HPLC spectrum and mass spectrometry results of the target protein shown in SEQ ID No.5 after enzyme digestion are as follows: Figure 4 shown. Figure 4 The first figure shows the HPLC spectrum before enzyme digestion, and the second figure shows the HPLC spectrum of the substance obtained after 8 hours of enzyme digestion. At this time, the enzyme digestion is incomplete. For the convenience of comparison, the product at this time point is selected for analysis and identification. The blue circles in the first and second figures refer to the same substance, corresponding to the protein shown in SEQ ID No.6, and the red circle is the new substance peak after enzyme digestion, corresponding to the protein shown in SEQ ID No.5. The components shown in the red circle are identified by mass spectrometry. The sample to be tested with a molecular weight of M is combined with n positive charges. Therefore, its theoretical charge-to-mass ratio m / z=(M+n) / n. If the theoretical charge-to-mass ratio corresponds to the mass spectrometry analysis results, it can be proved that the desired target polypeptide is synthesized. The theoretical molecular weight after enzyme digestion is 14.3kDa, and its mass spectrometry results are consistent with the theoretical value, confirming that the protein of SEQ ID No.5 of the present invention is obtained after enzyme digestion.
[0107] Example 3: Peptide stability test
[0108] The peptide degradation products were separated and quantified by HPLC analysis, and their half-lives were calculated and compared with those of GLP-1(7-37) and dulaglutide.
[0109] The specific steps are as follows:
[0110] (1) Prepare 0.9% (w / v) physiological saline, filter and sterilize with a 0.22 μm filter membrane, and dilute the test sample with the physiological saline;
[0111] (2) Centrifuge HSA at 4°C, 3000 rpm for 10 min, and dilute the supernatant to 10% (v / v);
[0112] (3) The polypeptide was incubated with 10% (v / v) HSA at 37°C. After sampling at each time point, an equal volume of 80% (v / v) acetonitrile-water solution was added to terminate the enzymatic reaction. The supernatant was collected after centrifugation at 12000 rpm for 5 min.
[0113] (4) HPLC analysis was performed using a C18 analytical column (ZORBAX 300SB-C18). The HPLC conditions were as follows:
[0114] Phase A: Ultrapure water containing 0.05% (v / v) TFA
[0115] Phase B: 80% (v / v) acetonitrile-water solution containing 0.05% (v / v) TFA
[0116] Ultrasonic degassing after 0.22μm filter membrane filtration
[0117] Flow rate: 1mL / min
[0118] Initial B phase ratio: 10%
[0119] Detection wavelengths: 215nm and 254nm.
[0120] Data processing: The stability of the peptide can be determined by comparing the changes in the peak area of the target peak at each time point. Prism 9.5.1 was used to process the data.
[0121] like Figure 5 The results show that compared with GLP-1(7-37) (11.77 min), the protein of SEQ ID No. 5 has higher stability and exhibits a longer half-life in vitro (12.92 h), but is not as good as dulaglutide (half-life 54.98 h).
[0122] Example 4: Functional receptor cAMP response assay
[0123] The agonistic effect of the peptide compound on the receptor was determined by a functional assay, and the cAMP response of the rat insulinoma RIN-m5F cell line expressing the GLP-1 receptor was measured. The principle of this method is: intracellular cAMP is released by lysing the cells, and cAMP activates protein kinase A to catalyze protein phosphorylation reactions and consume ATP. The reduction of ATP is reflected in the weakening of the chemiluminescent signal, that is, the higher the cAMP level, the higher the activity of protein kinase A, the more ATP is consumed, and the weaker the chemiluminescent signal. The changes in intracellular cAMP levels after stimulation of the test sample were detected using a cAMP-dependent protein kinase A activity assay kit (Promega's cAMP-GloTM Max Assay kit).
[0124] The specific steps are as follows:
[0125] (1) Cell culture
[0126] The rat insulinoma cell line RIN-m5F was obtained from the Cell Resource Center of the Institute of Basic Medicine, Chinese Academy of Medical Sciences. The culture medium of the RIN-m5F cell line was RPMI 1640 medium supplemented with 10% (v / v) FBS and 1% (v / v) double antibody, the digestion solution was 0.05% trypsin + 0.03% EDTA, and the digestion time was about 2 minutes.
[0127] Use cells in the logarithmic growth phase, digest the cells, and resuspend them to obtain a cell suspension. Use a blood cell counting plate to count and dilute the cells to 50,000 cells / mL. Add 100 μL of cell suspension to each well of an opaque 96-well plate. Place the 96-well plate in a 37°C, 5% carbon dioxide incubator and culture for 2 days.
[0128] (2) cAMP response assay
[0129] a. Prepare peptides of different concentrations (system 40 μL, the specific test concentrations are shown in the table below)
[0130]
[0131] b. Remove the medium from the 96-well plate and add 100 μL PBS to each well to wash twice.
[0132] c. Dilute the peptide sample with PBS. Add different concentrations of peptide to the 96-well plate by gradient dilution method. Set up 3 replicate wells for each concentration and incubate at 37℃ for 5 minutes.
[0133] d. Add 10 μL of cAMP detection solution (1 mL cAMP-Glo TM ONE-Buffer + 10μL PKA, invert to mix, do not vortex, in addition, because it cannot be frozen or stored, the test solution needs to be prepared immediately before use), and shake the 96-well plate for 1-2 minutes to mix thoroughly. Incubate at room temperature (22°C) for 20 minutes.
[0134] e. Add 50 μL of The 96-well plate was shaken for 1-2 minutes and then incubated at room temperature (22°C) for 10 min.
[0135] f. Read the relative chemiluminescence unit (RLU) using the chemiluminescence detection module of the microplate reader, and use Prism9.5.1 to draw the concentration response curve of each compound and calculate the EC 50 value.
[0136] The results are as follows Figure 6 EC of GLP-1(7-37), the protein of SEQ ID No.5 of the present invention, and Dulaglutide50 The values were 37.4 nM, 2.265 μM, and 66.26 nM, respectively. SEQ ID No. 5 has receptor agonist activity similar to that of GLP-1(7-37), indicating that the protein can normally activate GLP-1R.
[0137] Example 5: Confocal microscopy to characterize protein phase separation results
[0138] Confocal microscopy is the most commonly used experimental instrument to characterize protein liquid-liquid phase separation. It can most intuitively display whether the protein has liquid-liquid phase separation, the current state of liquid-liquid phase separation, and protein aggregation. In this experiment, since the peptide does not have a fluorescent label, it is observed under bright field conditions. The scanning speed is 1024HZ for preview and image acquisition.
[0139] In order to study whether the protein of SEQ ID No.5 can undergo LLPS in the presence of crowding agent PEG in vitro, the liquid-liquid phase separation state at different peptide concentrations and different PEG concentrations was detected and observed under a confocal microscope. Figure 7 As shown in the figure: In the absence of PEG, as the protein concentration increases, the peptide can undergo spontaneous phase separation at a higher concentration (30μM), and when PEG is added, the peptide can undergo LLPS even at a lower protein concentration (20μM), which not only shows that high-concentration proteins are more likely to undergo LLPS, but also shows that increasing the PEG concentration can reduce the threshold for protein LLPS, that is, PEG mediates and promotes the liquid-liquid phase separation of recombinant peptides in vitro. When the PEG concentration is 15%, it has the best phase separation performance. The above experiments were all carried out at room temperature (22°C).
[0140] In the presence of 48 mg / mL HSA, we investigated whether the presence of HSA affects the liquid-liquid phase separation state. Figure 8 As shown, it can be found that even at very low protein concentrations, the presence of HSA can induce phase separation. Therefore, it can be seen that under cell culture conditions, recombinant polypeptides can undergo phase separation. The above experiments were all carried out at room temperature (22°C).
[0141] To investigate the effect of temperature on the liquid-liquid phase separation state, at the test concentration, i.e., 10 μM, Fig. 9 As shown, the change in temperature has little effect on the state of the solution. When at room temperature or low temperature, the lower solution concentration cannot promote the occurrence of solution phase separation. However, when the temperature rises to 37°C, the formation of droplets can be observed.
[0142] Example 6: Intraperitoneal glucose tolerance test (IPGTT)
[0143] 6-8 weeks old male SD rats were randomly divided into five groups and subcutaneously injected with 200 μL normal saline, 1.25 μM dulaglutide, and 2.5 μM SEQ ID No.5, fasted overnight, and then fasting blood glucose was measured and glucose tolerance test was performed to draw blood glucose curve. The specific steps are as follows:
[0144] a. At 5 pm the day before the experiment, the mice were placed in clean cages and fasted for 16 hours until 9 am the next day. During the fasting period, the mice maintained normal drinking water.
[0145] b. The glucose tolerance test started at 9 am the next day.
[0146] c. Determination of fasting basal blood glucose: Use scissors to cut off the end 1-2 mm of the rat's tail, gently squeeze the rat's tail to allow the blood to concentrate into a drop, and use a blood glucose meter to measure the fasting blood glucose. The measured value is considered the blood glucose value at 0 minutes.
[0147] d. Oral infusion of glucose: 2 g glucose per kg body weight (50% glucose solution must be prepared in advance).
[0148] e. Measure the blood glucose level of each rat at 60min, 120min, and 180min after sugar infusion.
[0149] The results are as follows Fig.10 As shown, compared with normal saline, 2.5 μM of the protein of SEQ ID No. 5 can inhibit the increase of blood glucose in rats.
[0150] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A GLP-1RAs derivative, characterized in that The fusion protein consists of the amino acid sequence of GLP-1RAs from the N-terminus to the C-terminus - the linker sequence - the phase separation sequence; The phase separation sequence is the amino acid sequence of eIF4G (13-97) as shown in SEQ ID No. 4 or an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or about 100% homology to the sequence; The GLP-1RAs are GLP-1(7-37) or its analogs, or derivatives of GLP-1(7-37), or derivatives of GLP-1(7-37) analogs, or exendin-4(1-39) or its analogs, or derivatives of exendin-4(1-39), or derivatives of exendin-4(1-39) analogs; Preferably, the analog of GLP-1(7-37) is selected from GLP-1(7-36), wherein the amino acid at position 8 of GLP-1(7-37) is Ala, Gly, Val, Leu, Ile, Lys, Aib, (1-aminocyclopropyl)carboxylic acid, (1-aminocyclobutyl)carboxylic acid, (1-aminocyclopentyl)carboxylic acid, (1-aminocyclohexyl)carboxylic acid, (1-aminocycloheptyl)carboxylic acid or (1-aminocyclooctyl)carboxylic acid, the amino acid at position 22 is Gly, Glu or Aib, the amino acid at position 26 is Lys or Arg, the amino acid at position 34 is Lys, Glu, Asn or Arg, and the amino acid at position 36 is Arg, Gly or Lys; Preferably, the analog of GLP-1(7-37) is Gly 8 ,Glu 22 ,Gly 36 GLP-1(7-37), the amino acid sequence is shown in SEQ ID No. 2; Preferably, the analog of exendin-4(1-39) is selected from exendin-4(1-31), Y 31 exendin-4(1-31), desAla 35 exendin-4(1-39), des-Pro 36 exendin-4(1-39), des-Pro 36 ,Pro 37 exendin-4(1-39), des-Pro 36 ,Pro 37 ,Pro 38 exendin-4(1-39).
2. The GLP-1RAs derivative according to claim 1, characterized in that The linker sequence is GGGGSGGGGSGGGGS.
3. The GLP-1RAs derivative according to claim 2, characterized in that Its amino acid sequence is shown in SEQ ID No.
5.
4. A pharmaceutical composition, characterized in that Containing the GLP-1RAs derivative according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
5. Use of the GLP-1RAs derivative according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 in the preparation of a medicament for preventing or treating or delaying the progression or onset of the following diseases: type I and type II diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, hyperglycemia, hypercholesterolemia, dyslipidemia, hyperlipidemia, obesity, hypertension, syndrome X, atherosclerosis; Preferably, the diabetic complications are nephropathy, retinopathy, neuropathy, and cataracts; Preferably, the medicament is used to delay or prevent the development of type II diabetes; Preferably, the medicament is for reducing food intake, reducing β-cell apoptosis, increasing β-cell function and β-cell mass and / or restoring glucose sensitivity of β-cells.
6. A nucleic acid, characterized in that The nucleic acid encodes the GLP-1RAs derivative according to any one of claims 1 to 3.
7. An expression vector, characterized in that: The expression vector comprises the nucleic acid of claim 6; Preferably, the expression vector is a plasmid vector; Preferably, the plasmid vector is selected from pET-22a(+), pET-28a(+), pET-30a(+), and pET-33b(+).
8. A host cell, characterized in that The host cell comprises the expression vector of claim 7; Preferably, the host cell is Escherichia coli; Preferably, the host cell is Escherichia coli BL21 (DE3), Escherichia coli Rosetta (DE3), Escherichia coli Mach1-T1 and / or Escherichia coli DH5α.
9. A method for preparing the GLP-1RAs derivative according to any one of claims 1 to 3 using recombinant DNA technology, characterized in that: The method comprises the following steps: (a) introducing a nucleic acid sequence encoding the GLP-1RAs derivative into a host cell, (b) cultivating the host cell, and (c) isolating the GLP-1RAs derivative from the culture; Preferably, the nucleic acid sequence is introduced into the host cell via the expression vector pET-28a(+); Preferably, the host cell is Escherichia coli BL21 (DE3), Escherichia coli Rosetta (DE3), Escherichia coli Mach1-T1 and / or Escherichia coli DH5α.
10. The method according to claim 9, characterized in that (a) introducing a nucleic acid sequence encoding a GLP-1RAs derivative as shown in SEQ ID No.5 into a host cell; (b) cultivating the host cell; (c) isolating a fusion protein as shown in SEQ ID No.6 from the culture, purifying the fusion protein by HPLC, cleaving the fusion protein with enterokinase, and purifying the fusion protein again by HPLC to obtain the GLP-1RAs derivative as shown in SEQ ID No.5; Preferably, the recombinant Escherichia coli is cultured at 35-40°C for 10-12h to obtain a seed solution, and then inoculated into a culture medium at an inoculum amount of 0.1v / v%-2v / v% and cultured until the OD600 value of the fermentation liquid reaches 0.6-0.8, IPTG with a final concentration of 0.05-1mM is added for induction, and the fermentation is terminated after induction at 25-40°C for 6-12h, and the fermented bacteria are crushed and extracted, and after preliminary purification by HPLC, they are digested with enterokinase at 4-37°C for 8-72h and purified again by HPLC to obtain the GLP-1RAs derivative shown in SEQ ID No.5; the digestion buffer component is 24-26mM Tris-HCl, pH7.9-8.1; Preferably, the bacterial cells are suspended in a fragmentation buffer, the bacterial cells are fragmented and then centrifuged to collect the obtained inclusion body precipitate, the inclusion body precipitate is washed with a washing buffer, the washed inclusion bodies are dissolved by adding an inclusion body dissolution buffer at a pH of 12-13 according to a protein concentration of 5 to 55 g / L, and the dissolved fusion protein is centrifuged to remove insoluble impurities; the fragmentation buffer composition is 24-26 mM Tris-HCl, 9-11 mM imidazole, 170-190 mM NaCl, pH 7.9-8.1; the washing buffer composition is 24-26 mM Tris-HCl, 9-11 mM imidazole, 170-190 mM NaCl, 9-11 mM EDTA, 1.5-2.5% Tween 20, pH 7.9-8.1; the inclusion body dissolution buffer composition is 24-26 mM Tris-HCl, 1.5-2.5% Tween 20, pH 12.9-13.1; Preferably, the pH of the fusion protein supernatant solution after centrifugation is adjusted to 8-9, and 0.2-0.4% sodium lauryl sarcosine is added to clarify the solution; Preferably, the HPLC conditions are: C18 reverse phase column, phase A: ultrapure water containing 0.05% (v / v) TFA; Phase B: 80% (v / v) acetonitrile-water solution containing 0.05% (v / v) TFA; flow rate: 1-6 mL / min; detection wavelength: 215 nm and 254 nm.
Citation Information
Cited By
GLP-1 variants and uses thereof
CN119569847A
